Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury.
Hubbard WB, Spry ML, Gooch JL, Cloud AL, Vekaria HJ, Burden S, Powell DK, Berkowitz BA, Geldenhuys WJ, Harris NG, Sullivan PG.
Hubbard WB, et al. Among authors: berkowitz ba.
Brain. 2021 Dec 31;144(12):3788-3807. doi: 10.1093/brain/awab341.
Brain. 2021.
PMID: 34972207
Free PMC article.
Pioglitazone, an FDA-approved compound, has been shown to target the novel mitochondrial protein mitoNEET and produce short-term neuroprotection and functional benefits following traumatic brain injury. ...
Pioglitazone, an FDA-approved compound, has been shown to target the novel mitochondrial protein mitoNEET and produce short-term neur …